Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Published Medical Literature

Clinical Implications of a Complex Karyotype in AML in Children
Variant Acute Promyelocytic Leukemia: Genetic Knowledge May Help to Guide Treatment
Real-World Practice: Venetoclax Combinations in Patients With AML in Israel
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related AML
Acute Myeloid Leukemia and Spontaneous Splenic Rupture: Case Report
Mesothelin Under Study as Diagnostic and Therapeutic Target in AML
Consolidation Treatment in AML: Comparing Intermediate and High Dosing of Cytarabine
MLL Gene Rearrangements in Pediatric AML: Case Report
Potential Drug Candidates Identified for Pediatric Subtype of AML
Can Next-Generation Sequencing Help to Improve Outcomes in Elderly Patients With AML?
Is Lenalidomide Effective in Pediatric Patients With Resistant AML?
Older Patients With Untreated AML: Azacitidine Versus Triplet Regimen
Pilot Study of Vincristine Sulfate Liposome Injection in Resistant AML
Impact of Induction Chemotherapy on RAS Mutations in AML
In Vitro Responsiveness to Chemotherapy May Predict Responses to Treatment in AML
MRD Assessment: Refining Complete Remission in Elderly Patients With AML
How to Improve Adherence to Oral Medications in AML: Ask Patients
Reduced-Intensity Conditioning Regimen: Effect on Outcomes After Transplantation in AML
Thioridazine Under Study for Dopamine Receptor D2–Positive AML
What Is the Optimal Number of Chemotherapy Courses for Younger Patients With AML?
Large-Scale Study of AML, Venous Thromboembolism, and Hospitalization Rates
Maintenance Therapies After Hematopoietic Stem Cell Transplant in AML
Allogeneic HCT for AML: Long-Term Follow-up for Late Morbidities
First-in-Class LSD1 Inhibitor Under Study in Resistant AML
Combination of Venetoclax and Hypomethylating Agent for Favorable-Risk AML
Risk for Long-Term Complications in Younger Survivors of AML
Prognostic Power of Best Responses Under Study in Resistant AML
Integrated Palliative and Oncology Care for Patients With AML
Older Patients, Newly Diagnosed AML: Venetoclax-Based Combination Therapy
Treatment Advances in Secondary AML and Older Populations: The Age of Abundance
Allogeneic HSCT and AML: Prognostic Impact of Unsuccessful Cytogenetic Analysis at Baseline
Azacitidine Maintenance After Transplant in High-Risk AML
Pilot Program for Safely Administering Outpatient Chemotherapy Amid COVID-19
Novel PLK1 Inhibitor Plus Decitabine or Cytarabine Under Study in Resistant AML
TP53 Gene Mutations and Azacitidine Response in AML
Outpatient Chemotherapy Regimen Under Study in Pediatric AML
Marker Chromosome: Poor Prognostic Factor in AML After Allogeneic HSCT?
Beyond Survival: A Quality-Adjusted Analysis of Glasdegib in AML
Gene Mutations and Survival Outcomes in Older Patients With AML
Stem Cell Transplantation Followed by Cytarabine Chemotherapy for AML
Does Ibrutinib Enhance the Efficacy of Decitabine in AML?
Therapeutic Update in AML: Genomic Assessment Is Key
Lipid Core Nanoparticles Plus Etoposide With Transplantation for AML
Combination Therapy Under Study in Resistant FLT3-ITD–Mutated AML
Sorafenib Maintenance After Stem Cell Transplantation in FLT3-ITD AML
Update on Total-Body Irradiation in Children With de Novo AML
Therapeutic Considerations for Patients With AML Older Than Age 80
Can Dasatinib Overcome Resistance to FLT3 Inhibition in AML?
Can Immunoglobulin Expression Predict Survival in Patients With AML?
Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?
Low-Dose Cytarabine Plus Glasdegib in AML
Differentiation Syndrome With IDH Inhibitors in Resistant AML: FDA Analysis
Do CSF3R Mutations Affect Prognosis for Children With Favorable-Risk AML?
Secondary AML Risk Factors After Stem Cell Transplantation
Comparing AML Induction Regimens After Failure of Hypomethylating Agents
AML and Checkpoint Inhibitors: Outcomes With Cyclophosphamide After Transplantation
Venetoclax-Based Regimen for Patients With AML Ineligible for Intensive Chemotherapy
Predictors of Outcomes During Induction Chemotherapy for Patients With AML
Rare Case of Dual AML and Multiple Myeloma: Combination Therapy Active for Both
Busulfan Versus Melphalan: Long-Term Outcomes After Transplantation for AML
Long-Term Outcomes for Children With AML: Vietnamese Retrospective Study
Hematopoietic Stem Cell Transplantation for AML: Role of Genetic Mutation
Maintenance Selinexor After Allo-HCT for High-Risk AML
BRIGHT AML 1019 Trial to Study Glasdegib Plus Chemotherapy in Acute Myeloid Leukemia
Preserving Cardiac Function With Dexrazoxane in Pediatric Patients With AML
10-Year Data on Allo-HCT: Reduced-Intensity Versus Standard Conditioning Regimens
Fine-Tuning Cytarabine Treatment in Children With AML to Improve Outcomes
Feasibility of Outpatient Intensive Induction Chemotherapy for AML
Can Adding Venetoclax to FLAG-IDA Regimen Improve Outcomes in Patients With AML?
New Role Explored for Lenalidomide: With Chemotherapy for Older Patients With AML
Novel Combination of Lithium and Tretinoin for Treatment-Resistant AML
Additional Venetoclax-Inclusive Drug Combinations for Elderly Patients With AML
Aspacytarabine for Patients With AML Who Are Unfit for Standard Chemotherapy
Conditioning Intensity Before Transplantation May Affect Outcomes in AML
Sorafenib in FLT3/ITD-Positive AML: Impact of Co-occurring Mutations
Venetoclax-Based Regimen for Pediatric Patients With Resistant AML
Concordant AML in Twin Sisters: Impact of Prepubertal Cancer Treatment
Comparison of Conditioning Regimens Before Transplantation in Older Patients With AML
Can Early Cytogenetic Testing Improve Outcomes With HCT in AML?
Role of Isocitrate Dehydrogenase Inhibitors in AML Treatment
ADMIRAL Trial: Genetic Mutations in Patients With Resistant AML
Using Targeted Therapy in Older Patients With AML
Expression of Transcription Factors in Newly Diagnosed Acute Myeloid Leukemia
Epigenetic Alteration of HIST1 in Acute Myeloid Leukemia With NPM1 Mutation
Nivolumab Plus Front-Line Chemotherapy in Newly Diagnosed AML
How Does Gilteritinib Compare With Chemotherapy for FLT3 -Mutated AML?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.